Pyrazoloacridine Followed by Radiation Therapy in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme

Completed · Phase 1/Phase 2

Conditions studied: Brain and Central Nervous System Tumors

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of pyrazoloacridine followed by radiation therapy in treating adults who have newly diagnosed supratentorial glioblastoma multiforme.

Key facts

Study ID

NCT00006355

Run by

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Starts

2000-05-01

Expected to finish

2006-10-01

Last updated by the study team

2012-05-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Alabama at Birmingham Comprehensive Cancer Center — Birmingham, Alabama, United States
• H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
• Winship Cancer Institute of Emory University — Atlanta, Georgia, United States
• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States
• Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States
• Josephine Ford Cancer Center at Henry Ford Health System — Detroit, Michigan, United States
• Comprehensive Cancer Center at Wake Forest University — Winston-Salem, North Carolina, United States
• Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.